Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

New mouse models help study melanocytic cells for melanoma research.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

The QuantAnts machines can find cancer markers and create CRISPR targets for them.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Ritlecitinib can help about 14,000 people with severe hair loss.

Sorafenib can cause a unique skin reaction.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

CXCR2 in skin cells promotes tumor growth.

A woman's hair turned white after taking a cancer drug called dasatinib.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Compound 7p shows strong potential as an anticancer agent.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.